Search

Your search keyword '"MAP2K1"' showing total 405 results

Search Constraints

Start Over You searched for: Descriptor "MAP2K1" Remove constraint Descriptor: "MAP2K1"
405 results on '"MAP2K1"'

Search Results

1. Trametinib for a child with refractory Rosai–Dorfman–Destombes disease harboring a novel somatic mutation in MAP2K1.

2. Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.

3. Circ_0000069 promotes the development of hepatocellular carcinoma by regulating CCL25

4. Long-term clinical course of adult-onset refractory epilepsy in cardiofaciocutaneous syndrome with a pathogenic MAP2K1 variant: a case report.

5. Circ_0000069 promotes the development of hepatocellular carcinoma by regulating CCL25.

6. CIRC-0008798 and CIRC-0035967 as novel biomarkers in oral lichen planus and oral squamous cell carcinoma

7. Inhibition of the long non-coding RNA MALAT1 downregulates MAP2K1 to suppress the progression of hypopharyngeal squamous cell carcinoma

8. Human Genetics of Atrial Septal Defect

9. Cladribine chemotherapy of multifocal, multisystemic form of Rosai–Dorfman disease: literature review and case report

10. MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E.

11. Epilepsy in cardiofaciocutaneous syndrome: Clinical burden and response to anti‐seizure medication.

12. MAP2K1‐mutated melanocytic tumors have reproducible histopathologic features and share similarities with melanocytic tumors with BRAFV600E mutations.

13. Langerhans cell histiocytosis: current advances in molecular pathogenesis.

14. A case report of a blueberry muffin baby caused by congenital self-healing indeterminate cell histiocytosis

16. Langerhans cell histiocytosis: current advances in molecular pathogenesis

17. A case report of a blueberry muffin baby caused by congenital self-healing indeterminate cell histiocytosis.

18. Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.

19. Endothelial cell expression of mutant Map2k1 causes vascular malformations in mice.

20. Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

21. Cancer‐causing MAP2K1 mutation in a mosaic patient with cardio‐facio‐cutaneous syndrome and immunodeficiency.

22. Severe neuroglycopenic symptoms due to nonketotic hypoglycemia in children with cardio‐facio‐cutaneous syndrome.

23. Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

24. Clinical characteristics of 10 Chinese patients with melorheostosis and identification of a somatic MAP2K1 variant in one case.

25. Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children.

26. Recurrent p.H119Y variant in MAP2K1 expands the phenotypic spectrum of MAP2K1-related RASopathy.

27. Phoniatric, Audiological, Orodental and Speech Problems in a Boy with Cardio-Facio-Cutaneous Syndrome Type 3 (CFC 3) Due to a Pathogenic Variant in MAP2K1 – Case Study

28. Clinical characteristics of 10 Chinese patients with melorheostosis and identification of a somatic MAP2K1 variant in one case

29. Case report: The cardio-facio-cutaneous syndrome due to a novel germline mutation in MAP2K1: A multifaceted disease with immunodeficiency and short stature

30. Unique Case of Congenital Langerhans Cell Histiocytosis Presenting as Intrauterine Fetal Demise.

31. Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma

32. Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.

33. The Morpho-Molecular Landscape of Spitz Neoplasms.

34. Clinicopathological and Gene Mutation Analysis of 27 Cases with Extranodal Rosai–Dorfman Disease.

35. A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children.

36. A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children

37. Long Non-Coding RNA PART1 Promotes Proliferation, Migration and Invasion of Hepatocellular Carcinoma Cells via miR-149-5p/MAP2K1 Axis

38. Long-term clinical course of adult-onset refractory epilepsy in cardiofaciocutaneous syndrome with a pathogenic MAP2K1 variant: a case report.

39. Shikonin ameliorates injury and inflammatory response of LPS‐stimulated WI‐38 cells via modulating the miR‐489‐3p/MAP2K1 axis.

41. Recurrent Somatic MAP2K1 Mutations in Papillary Thyroid Cancer and Colorectal Cancer

42. Expanding spectrum of "spitzoid" lesions: a small series of 4 cases with MAP2K1 mutations.

43. Recurrent Somatic MAP2K1 Mutations in Papillary Thyroid Cancer and Colorectal Cancer.

44. Cross‐Sectional Imaging Useful in Melorheostosis

45. Cross‐Sectional Imaging Useful in Melorheostosis.

46. The Morpho-Molecular Landscape of Spitz Neoplasms

47. The effect of STAT1, miR-99b, and MAP2K1 in alcoholic liver disease (ALD) mouse model and hepatocyte.

48. Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis.

49. Oncogenic mutations within the β3‐αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies

50. Oncogenic mutations within the β3‐αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies.

Catalog

Books, media, physical & digital resources